There's been an alarming increase of respiratory and gastrointestinal viruses in the United States lately, causing anxiety about a so-called "quad-demic". According to surveillance reports, influenza, COVID-19, RSV and norovirus are at very high levels everywhere. While the surge aligns with patterns typical for this season, several epidemiologists view simultaneous infections of such proportions to pose risks not only to individual healthcare but public health.

The incidence of the quad-demic should vary with seasonal patterns, vaccination rates, and public health interventions. Each virus alone is relatively easy to manage; however, the effect of all together could lead to overburdening of health care facilities and increase risks for those at higher risk. Continuing surveillance, early testing, and proactive prevention measures will play an important role in the control of these infections going forward.

While the term "quad-demic" sounds daunting, it must be taken into perspective. For years, we have had all these viruses together, and we have the capabilities to mitigate some of the risk. Vaccination, proper hygiene and using common sense helps individuals get through the season unscathed. Is the quad-demic a permanent fixture or just another seasonal wave? Let's break this down.

What is the Quad-demic?

Typically, flu, COVID-19, and RSV have been the primary culprits behind seasonal respiratory infections. However, norovirus, a highly contagious stomach bug, has emerged as a fourth significant player, inducing fears of a more severe and widespread viral outbreak. According to the Centers for Disease Control and Prevention (CDC), the U.S. recorded nearly 500 norovirus outbreaks between August and December 2023, a substantial rise from the previous year’s numbers.

While the term "quad-demic" may sound ominous, the seriousness and consequences of such infections should be weighed in light of the U.S. healthcare system's experience with managing viral surges since the start of the COVID-19 pandemic.

1. Influenza (Flu)

Flu continues to be one of the most common and alarming seasonal illnesses. In the period spanning from 2023 to 2024, there were approximately 40 million cases of flu, and thousands of hospitalizations along with reported 47 deaths have been reported this season. Flu symptoms include fever, chills, cough, sore throat, muscle pain, and fatigue, with most recovering within a week or two but risky factors for severe illness effects occur in young children, elderly, and people with chronic conditions.

2. Covid-19

Despite its reduction from the first pandemic peak, COVID-19 is still rampant. The CDC estimates that alone between October and December 2023, there were between 2.7 and 5 million cases in the U.S. Hospitalization has increased by cities such as Los Angeles, Chicago, and New York. Symptoms are closely similar to the flu, fever, cough, and fatigue but uniquely presents in some cases as loss of taste and smell.

3. RSV

RSV is the most common cause of lower respiratory infections in infants, older adults, and immunocompromised individuals. While RSV peaked late in 2023 and early 2024, it continues to be a threat because it can lead to bronchiolitis and pneumonia. It is very similar to the common cold, presenting with symptoms such as congestion, runny nose, coughing, and fever, which can make it difficult to differentiate from flu or COVID-19 without testing.

4. Norovirus

Norovirus, also called the "stomach flu," is a highly contagious infection of the gastrointestinal tract, not a respiratory virus. It transmits quickly from contaminated food and water and contact with contaminated surfaces, causing such symptoms as diarrhea, vomiting, nausea, and stomach pain. Cases have shot up, the CDC said Monday, with reports of outbreaks surging compared with last year.

Is There a Challenge In Diagnosis Due to Overlapping Symptoms?

The greatest challenge during the quad-demic is how the four viruses are alike and thus make identification very hard with no testing applied. Most cases present symptoms common to all viruses: fever, tiredness, body pains, and respiratory, which includes coughing and congestions for influenza, COVID-19, and RSV; the other would be norovirus symptoms as nausea and vomiting can appear even in extreme influenza and COVID-19. This overlap increases the risk of misdiagnosis and delayed treatment, hence the need for early testing and proper medical guidance.

Also Read: Is US Preparing For A Quad- demic 2025?

Effective Prevention Strategies That Work

The best defense against these viruses is a combination of vaccines, hygiene, and lifestyle precautions. While lifestyle modifications are highlighted as part of the constant need to eat healthy, ensure daily movement and drinking adequate amount of fluids. There is a sure short two preventive strategies that are effective:

Vaccination

• Flu vaccine: Annual flu shots reduce the severity of infection, allergic flare ups and hospitalizations.
• COVID-19 vaccine: Though COVID-19 cases have declined, vaccination remains critical in preventing severe outcomes.
• RSV vaccine: Available for those aged 60 years and older, especially those with underlying conditions.
• Norovirus vaccine: No vaccine is yet available, but mRNA vaccine research is in progress.

Hygiene and Sanitation

• Washing hands frequently with soap and water for at least 20 seconds, especially after public exposure.
• Disinfect frequently touched surfaces regularly, use sanitiser when outside.
• Avoid close contact with infected people and wear masks.

Do You Need To Wear A Mask All The Time?

While debates on masked wear continue on, experts on mask-wear affirm that this does not only have a historical precedent but works towards reducing airborne viruses spreading within the environments. Hospitals, though, ensure masking in key sections of themselves. Publicized mask-wear remains a discretion, though massing indoors still goes a longer way in cases like peak flu seasons.

If you notice the symptoms of these viruses, then it's best to be confined at home and avoid having face-to-face interaction with others and seek immediate attention from your physician if your condition worsens. Quarantining for some days can decrease the spread of infection.

As we move into the first half of 2025 and beyond, staying informed and proactive is the best strategy for maintaining health and avoiding unnecessary panic. The key takeaway? Stay vigilant, but don’t be alarmed—these viruses are here, but so are the means to fight them.

The National Pharmaceutical Pricing Authority (NPPA), under the Department of Pharmaceuticals has revised the maximum retail prices of 543 anti-cancer medicines. The new rates are set to take effect from November 9, 2026. However, it does not reduce the price of Keytruda, a blockbuster immunotherapy drug used to treat more than 21 types of cancer.

India’s drug price regulator released the revised price list on October 28. The revisions come after the government’s decision to rationalise trade margins on 137 non-scheduled anti-cancer drugs, aiming to improve affordability and access to life-saving cancer treatment.

It also comes after the Supreme Court recently questioned hospitals’ staggering mark-ups on certain cancer medicines during a PIL hearing.

The updated list reflects pricing information submitted by pharmaceutical companies up to October 27. It will be revised further as manufacturers submit updated prices.

Which Cancer Drugs Have Become Cheaper?

Also read: Cancer Drug At ₹11,000, Hospital Bill ₹1.3 Lakh: SC Calls Hospital Mark-Ups ‘Loot’ & ‘Dacoity’

Several cancer medicines have undergone drastic price reductions, including drugs used in chemotherapy, targeted therapy and other forms of cancer treatment.

For instance, the price of Anarzole, a brand of anastrozole used in hormone-sensitive breast cancer, has fallen from ₹695.76 to ₹73 for a pack of 10 tablets containing 1 mg each.

The revised price of Azacytin, a 100 mg azacitidine injection marketed by Dr Reddy’s Laboratories, has dropped from ₹6,337 to ₹1,495.04.

Bevacizab, a bevacizumab injection marketed by Abbott Healthcare, has fallen from ₹21,767.70 to ₹5,930.13 for a 4 ml vial.

Other reductions include:

• Dasanat 20: The price of a pack of 60 dasatinib tablets has fallen from ₹2,812.50 to ₹1,085.93.
• Debrumab 60 mg: The price of a denosumab injection has dropped from ₹22,031.25 to ₹5,941 per pre-filled syringe.
• Enuta: The price of a pack of 28 enzalutamide capsules has fallen from ₹6,578.20 to ₹2,232.
• Fulbreca: The price of a 5 ml fulvestrant injection has dropped from ₹26,072.16 to ₹5,491.

Keytruda’s Price Remains Unchanged

Also read: From ₹6.2 Lakh To ₹15,900: Kerala Health Minister Defends Generic SMA Drug But Parents Want Safety Assurance

Despite the reductions across several cancer drug brands, the listed price of Keytruda remains unchanged at ₹2,16,500.

Keytruda, whose generic name is pembrolizumab, is an immunotherapy drug that works by helping the immune system recognise and attack cancer cells. It is used in the treatment of multiple cancers depending on the cancer type, disease stage and other clinical factors.

The drug is part of a class of medicines known as immune checkpoint inhibitors. These treatments target mechanisms that cancer cells can use to evade immune responses, helping the body’s immune system to mount a stronger attack against the tumour.

Other expensive brands, including Tagrisso, Tecentriq, Darzalex and Imfinzi, were also reported to remain unaffected by the recent price regulations.

This brings us to an important limitation of the latest revision. Reductions in the prices of selected brands do not automatically translate into lower prices for every cancer medicine.

Why Cancer Drug Prices Have Been Revised?

The latest price revisions follow the NPPA’s October 17 decision to introduce Trade Margin Rationalisation (TMR) for 137 identified non-scheduled anti-cancer drugs.

Trade margins are the mark-ups added along the distribution and sales chain. Under the measure, trade margins for the identified medicines have been capped at 30% of the maximum retail price. The intervention is intended to address excessive margins, make medicines more affordable and improve access to treatment.

The medicines covered include immunotherapy drugs used in more than 20 types of cancer, denosumab used in certain breast and prostate cancer cases, pegfilgrastim to help prevent chemotherapy-induced neutropenia, and bevacizumab, which is used for certain colorectal, ovarian and cervical cancers.

Dr. Sandeep Nayak, Chairman of Oncology, MACS-Renova Oncology Institute, KIMS Hospital, Bangalore reacted to NPPA's move. He said, "The price control introduced by the government is a positive move, as it helps bring greater uniformity to profit margins on drugs. Since the government is not controlling manufacturing prices, the move could benefit patients while bringing greater transparency to the market."

He also said that the measure could also contribute to addressing the issue of counterfeit medicines in the long run as well.

He said, "An initial assessment of the list of more than 500 drugs from various pharmaceutical companies suggests that the move is largely logical. While a detailed examination is required, the prices of many original manufacturers appear to have remained unchanged, indicating that their margins may already have been within a reasonable range."

He also expressed his concern about the drug's viability for the manufacturers.

He said, "My only worry remains that the low cost life saving drug should remain viable to manufacture and sell (eg. Tamoxifen). In the past we have seen that getting affected because of price control."

Will Price Cuts Help Cancer Patients?

Cancer treatment costs extend beyond medicines to include surgery, radiation therapy, diagnostic tests, hospitalisation and follow-up care. For patients who pay out of pocket, even a reduction in the cost of a drug can help ease some of the financial burden.

However, only patients using brands whose MRPs have fallen may see savings, while those using medicines whose prices remain unchanged may not benefit from this revision.

Patients and caregivers can check the NPPA’s updated price list or the government’s Pharma Sahi Daam app to verify the revised MRP of a specific medicine. They should consult their treating oncologist before making any changes to a prescribed treatment.

The hype around Eli Lilly’s experimental weight-loss drug retatrutide is already at peak. It may be fueled further after its Phase 3 clinical trials reported that some people with obesity and obstructive sleep apnea breathe were able to breathe more easily during sleep. Furthermore, the condition seemed to be completely resolved in at least 1 in 4 patients with type 2 diabetes.

Published in The New England Journal of Medicine recently, the trials found that retatrutide significantly lowered breathing interruptions during sleep compared to a placebo. The effects were seen in adults with moderate-to-severe obstructive sleep apnea, both with and without type 2 diabetes.

According to study co-author Dr. Virend Somers, a cardiologist and professor of medicine at the Mayo Clinic, sleep apnea was completely resolved in around 15% of participants with type 2 diabetes and 25% of those without diabetes.

Findings From Retatrutide Phase 3 Clinical Trials

The two Phase 3 trials were done on 691 adults with moderate-to-severe obstructive sleep apnoea and a body mass index of at least 27. Of these, 448 had type 2 diabetes and 243 did not.

The participants received once-weekly injections of retatrutide at doses of 4, 9 or 12 milligrams, or a placebo. Researchers followed them for 80 weeks.

The main finding was the change in the apnoea-hypopnea index (AHI), which measures the average number of times a person experiences pauses in breathing or episodes of shallow breathing per hour of sleep.

Retatrutide reduced AHI more than placebo in both trials. Participants also lost approximately 12%-22% of their body weight, depending on the dose and study group. The findings indicate that the drug could help reduce the severity of sleep apnea. However, it was only observed in a subset of participants. So, it must not be interpreted that weight loss along resulted in reversal of sleep apnea.

Also read: Retatrutide Driving Peptide-Linked Emergency Hospital Admissions In Australia: What Are The Risks?

Could Weight-Loss Drugs Improve Sleep Apnea?

Obstructive sleep apnea occurs when the upper airway repeatedly narrows or becomes blocked during sleep, interrupting normal breathing. Obesity can increase the risk because excess tissue around the neck and upper airway can contribute to airway obstruction.

Retatrutide targets three hormone receptors involved in metabolism - GLP-1, GIP and glucagon. By regulating appetite, blood sugar regulation and energy metabolism, the drug can result in substantial weight loss.

The researchers believe that reductions in body weight may help reduce airway obstruction. Participants also experienced improvements in several cardiovascular risk factors, including systolic blood pressure, LDL cholesterol and systemic inflammation.

Somers told Fox News Digital, “OSA is often under-diagnosed and under-treated.” He said he was surprised by the magnitude of the benefit among participants with type 2 diabetes, as well as the reduction in sleep apnoea severity.

Also read: Burning Skin, Panic Attack & Depression: ‘Godzilla’ Weight Loss Drug Retatrutide Linked To 129 Symptoms

Can Retatrutide Replace CPAP?

Continuous positive airway pressure (CPAP), which delivers pressurised air through a mask to keep the airway open during sleep, is the primary treatment for obstructive sleep apnoea.

The trials included participants who used CPAP and those who did not. Researchers observed that CPAP use generally declined during the study, but this does not mean patients should stop using the device without doctor’s advice.

Other treatments include mandibular advancement devices, which help keep the airway open, and positional therapy for people whose symptoms worsen when sleeping on their backs.

Sleep Apnea Is Linked With Serious Disorders

Sleep apnea is a sleep disorder in which breathing repeatedly stops and starts during sleep. The most common type, obstructive sleep apnoea, occurs when throat muscles relax and temporarily block the airway. Symptoms include loud snoring, gasping during sleep, morning headaches and daytime fatigue.

Obesity is a major risk factor because excess tissue around the neck can narrow the airway. Untreated sleep apnoea can lead to high blood pressure, cardiovascular disease and difficulties managing blood sugar.

The Supreme Court of India has slammed the steep mark-ups private hospitals charge for cancer medicines, describing excessive pricing as “loot” and “dacoity” as it considers whether tighter regulations are needed to protect patients.

During a hearing on October 27, a bench of Justices Vikram Nath and Sandeep Mehta reserved its verdict on petitions seeking stronger controls on the prices of medicines.

The court highlighted the financial burden faced by people who need life-saving treatment, especially those battling cancer, and questioned whether the government’s current pricing framework protects patients from excessive healthcare costs.

Cancer Injection Costs ₹11,000 But Billed At ₹1.3 lakh

Also read: India Caps Cancer Drug Trade Margins At 30%; Patients May Save Rs 2,500 Crore Annually

The Court was hearing a public interest litigation (PIL) filed by advocate Kishan Chand Jain who sought seeking mandatory generic drug prescriptions, stricter initial price controls on non-scheduled medicines, and statutory margin caps on medical devices under the Drug Price Control Order (DPCO).

One example cited by the court is of a medicine distributor whose wife was undergoing cancer treatment at a prominent private hospital.

According to the account presented during the hearing, the distributor offered to procure a chemotherapy injection at his dealer price of ₹11,000, but the hospital charged ₹1.3 lakh for the same medicine.

“Can you show any justification for this loot, please? Why this difference? Where does the money go?” the bench asked.

The judges also questioned the pricing of routine hospital supplies. A saline drip line with a cost ₹15 was reportedly being billed to patients at ₹250.

These examples raised questions about how medicine procurement costs, manufacturer discounts, hospital operating expenses and final patient bills are accounted for.

The Court also addressed Centre's recent decision to cap trade margins for anti-cancer drugs at 30 percent but how nearly 90 percent of medicines available in the market remain outside the purview of the Drug Price Control Order (DPCO).

"Why is the DPCO in place at all? The government is allowing this to happen. There have been three parliamentary committees on this. And their outcome is not very convenient to people who pull the strings, let us tell you," the Bench remarked.

Medicine Price Caps Under Scrutiny

Also read: 137 Cancer Drugs To Cost Up To 70% Less From November 9: NPPA Caps Trade Margins

India regulates prices of scheduled medicines under the Drugs (Prices Control) Order, 2013. The government has also introduced trade margin limits for a few anti-cancer medicines.

During the hearing, the Centre said trade margins on 137 anti-cancer medicines had been capped at 30% of the maximum retail price (MRP), a measure it estimated could save patients around ₹2,500 crore annually.

The court questioned why such interventions were limited to only a few medicines and whether a bigger and more comprehensive drug regulation was needed.

The petitions seek measures including mandatory generic prescriptions, controls on the initial prices of non-scheduled medicines and limits on trade margins for medical devices.

Hospitals And Government Raise Concerns

Representing private hospitals, senior advocate Mukul Rohatgi argued that healthcare institutions must maintain round-the-clock infrastructure and cover substantial operating costs. He also raised concerns about patients bringing medicines from outside, including the risk of counterfeit products.

The Centre maintained that medicine pricing policy must balance affordability with investment, competition and the sustainability of the pharmaceutical sector.

Additional Solicitor General Aishwarya Bhati told the court that the government continued to review its rules. The bench questioned whether these considerations addressed patients’ limited bargaining power when they need life-saving treatment.

"Your calibration is too wayward. ₹11,000 to ₹1,30,000 is no calibration. When you talk of patients and life, should we have such capitalistic thinking. Hospitals can survive through other means. Not through this dacoity,” the bench remarked, according to reports of the proceedings.

The Supreme Court has reserved its verdict. Until the order is delivered, no new price cap should be assumed. The court’s decision could influence future regulation of medicine prices and hospital mark-ups.